Form 4: Sarepta Therapeutics Executive Louise Rodino-Klapac Reports Stock Transactions

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports the vesting of performance stock units, tax-related stock sales, and the grant of restricted stock units.

Summary

• On March 7, 2025, Louise Rodino-Klapac vested 5,500 shares under a performance stock unit (PSU) award.
• On March 10, 2025, 924 shares were sold to cover tax obligations related to restricted stock units vesting at a price of $100.13.
• An additional 2,539 shares were sold on March 10, 2025, at $100.13 to cover tax obligations related to the vesting of PSUs.
• Also on March 10, 2025, Rodino-Klapac was granted 8,276 restricted stock units (RSUs).
• Rodino-Klapac also acquired 16,644 stock options on March 10, 2025, exercisable starting March 10, 2026, and expiring on March 10, 2035.
• Following these transactions, Rodino-Klapac directly owns 84,631 shares of common stock and 16,644 stock options.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices and insider transactions, which are neither overwhelmingly positive nor negative. The vesting of PSUs suggests achievement of company milestones, while the stock sales are routine for tax purposes.

Positives

• The vesting of PSUs indicates the company achieved certain milestones as determined by the Compensation Committee.
• The grant of RSUs and stock options suggests continued confidence in the executive's performance and the company's future.

Future Outlook

The RSUs will vest in equal installments on each anniversary of the grant date over four years, and the stock options vest monthly starting March 10, 2026.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It is common for executives to receive stock-based compensation and to sell shares to cover tax obligations upon vesting.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry to align the interests of executives with those of shareholders.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and terms of these awards are generally comparable across the industry, with vesting periods typically ranging from three to five years.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax-related sales.
• Employees may be indirectly impacted by the company's performance, which influences the vesting of performance-based equity awards.

Key Dates